Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00896961 · ClinicalTrials.gov registry record · NA
EF5 to Evaluate Tumor Hypoxia in Patients With High-Grade Soft Tissue Sarcoma or Mouth Cancer
A NA study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- NA
- Development phase
- 120
- Enrollment target
NCT00896961: Clinical Trial NA study, sponsored by National Cancer Institute (NCI).
NCT00896961 is a NA study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 120 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00896961, a NA study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- NA
- Development phase
- 120 participants
- Enrollment target
Study Summary
This laboratory study is using EF5 to evaluate tumor hypoxia in patients with high-grade soft tissue sarcoma or mouth cancer. Using the drug EF5 to measure the oxygen level in tumor cells may help in planning cancer treatment
Interventions
- OTHER pharmacological study
- OTHER diagnostic laboratory biomarker analysis
- DRUG EF5
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2001-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00896961
The ClinicalTrials.gov registry entry for NCT00896961 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which pharmacological study is the first listed.
NCT00896961 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00896961 about?
NCT00896961 is a clinical study titled "EF5 to Evaluate Tumor Hypoxia in Patients With High-Grade Soft Tissue Sarcoma or Mouth Cancer". This laboratory study is using EF5 to evaluate tumor hypoxia in patients with high-grade soft tissue sarcoma or mouth cancer. Using the drug EF5 to measure the oxygen level in tumor cells may help in planning cancer treatment
What is the current status of trial NCT00896961?
This trial is currently terminated. It is a NA study. The enrollment target is 120 participants. The study started on 2001-08.
What interventions are being tested in trial NCT00896961?
The interventions under investigation include: pharmacological study (OTHER), diagnostic laboratory biomarker analysis (OTHER), EF5 (DRUG).
Who is sponsoring clinical trial NCT00896961?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.